poisar

Stocks · News reference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

Henry Khederian

Shares of BioAffinity Technologies are surging Thursday after securing a key Hong Kong patent for its CyPath Lung diagnostic.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BIAFBIAFW
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Benzinga Newsdesk

    Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum

    Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian marketAsia accounts for nearly two-thirds of lung cancer cases worldwidebioAffinity Technologies, Inc. (NASDAQ:BIAF,

    BIAF